Ginkgo Bioworks Holdings (DNA) Non Operating Investment Income (2020 - 2026)

Ginkgo Bioworks Holdings' Non Operating Investment Income history runs 7 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• Quarterly Non Operating Investment Income rose 67.13% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.9 million (up 53.52% YoY) and the FY2025 annual result came in at -$16.4 million, up 43.07% from the prior year.
• Non Operating Investment Income was -$1.2 million for Q1 2026 at Ginkgo Bioworks Holdings, up from -$16.2 million in the prior quarter.
• Across five years, Non Operating Investment Income topped out at $3.7 million in Q3 2025 and bottomed at -$38.7 million in Q2 2022.
• A 5-year average of -$9.1 million and a median of -$6.4 million in 2023 frame the typical range for Non Operating Investment Income.
• Annual changes were most pronounced in 2023 — Non Operating Investment Income slumped 1966.21% — and 2025, when it jumped 153.3%.
• Ginkgo Bioworks Holdings' Non Operating Investment Income stood at -$13.4 million in 2022, then increased by 25.03% to -$10.0 million in 2023, then fell by 25.3% to -$12.5 million in 2024, then slipped by 28.92% to -$16.2 million in 2025, then jumped by 92.49% to -$1.2 million in 2026.
• Business Quant data shows DNA's Non Operating Investment Income at -$1.2 million in Q1 2026, -$16.2 million in Q4 2025, and $3.7 million in Q3 2025.